Skip to main content

Table 3 Observed versus expected receipt of focus drug in 2014

From: Temporal and geographic variation in the systemic treatment of advanced prostate cancer

Region Docetaxel (%) Cabazitaxel (%) Sipuleucel-T (%) Radium-223 (%) Abiraterone (%) Enzalutamide (%) Row Total
New England 12 (27.3) 0 (0.0) 3 (6.8) 0 (0.0) 22 (50.0) 7 (15.9) 44
11 0 4 1 20 8  
Middle Atlantic 23 (21.5) 0 (0.0) 6 (5.6) 3 (2.8) 50 (46.7) 25 (23.4) 107
26 0 10 1 50 20  
South Atlantic 44 (26.0) 0 (0.0) 20 (11.8) 2 (1.2) 70 (41.4) 33 (19.5) 169
41 0 16 2 78 32  
East North Central 38 (22.0) 3 (1.7) 17 (9.8) 2 (1.2) 73 (42.2) 40 (23.1) 173
42 0 16 2 79 33  
East South Central 5 (14.7) 0 (0.0) 4 (11.8) 0 (0.0) 19 (55.9) 6 (17.6) 34
8 0 3 0 16 6  
West North Central 39 (45.3) 0 (0.0) 12 (14.0) 3 (3.5) 23 (26.7) 9 (10.5) 86
21 0 8 1 39 16  
West South Central 20 (21.1) 0 (0.0) 9 (9.5) 1 (1.1) 46 (48.4) 19 (20.0) 95
23 0 9 1 44 18  
Mountain 26 (21.1) 0 (0.0) 13 (10.6) 0 (0.0) 64 (52.0) 20 (16.3) 123
30 1 12 1 56 23  
Pacific 23 (15.6) 0 (0.0) 5 (3.4) 0 (0.0) 91 (61.9) 28 (19.0) 147
36 1 14 2 67 28  
Unknown 25 (37.3) 1 (1.5) 9 (13.4) 1 (1.5) 21 (31.3) 10 (14.9) 67
16 0 6 1 31 13  
Column Total 255 4 98 12 479 197 1045
  1. States within each geographic region:
  2. • New England: Connecticut, Maine, New Hampshire, Rhode Island, Vermont, Massachusetts
  3. • Middle Atlantic: New Jersey, New York, Pennsylvania
  4. • South Atlantic: Delaware, Washington D.C., Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia
  5. • East North Central: Illinois, Indiana, Michigan, Ohio, Wisconsin
  6. • East South Central: Alabama, Kentucky, Mississippi, Tennessee
  7. • West North Central: Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota
  8. • West South Central: Arkansas, Louisiana, Oklahoma, and Texas
  9. • Mountain: Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming
  10. • Pacific: Alaska, California, Hawaii, Oregon, Washington
  11. Number of patients (percent) in our study cohort who received the indicated focus drug as first-line therapy by geographic region in 2014 on the top line and number of patients expected to have received the indicated focus drug as first-line of therapy under the assumption of independence between geographic region and focus drug are also provided on the second line of each cell
\